In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Presentation, Treatment, and Long-Term Outcome of Intrasellar Chordoma

    Final Number:
    1257

    Authors:
    Abdul-Kareem Ahmed BS BA SM; Hassan Dawood; Timothy R. Smith MD PhD MPH

    Study Design:
    Other

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2017 Annual Meeting

    Introduction: Chordoma is a locally aggressive tumor arising from notochord remnants. Little is known about the characteristics and long-term prognosis of intrasellar chordoma. The purpose of this study was to determine common features, treatment approaches and survival characteristics of this rare clinical entity.

    Methods: Institutional databases at BWH/MGH were searched for intrasellar chordoma. The National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database November 2015 submission was queried for ‘chordoma’ (ICD-O-3 9370/3) occurring primarily in the ‘pituitary gland’ (Site C75.1). Using PubMed/NCBI, a comprehensive literature review of reported cases of intrasellar chordoma was conducted. From all sources, patient-level data was extracted where available. SEER was also queried for skull base chordoma. Kaplan-Meier statistical analyses were conducted with a primary endpoint of death. A p-value of less than 0.05 was considered significant.

    Results: A total of 89 cases were evaluated. Of these, 8 were a chondroid variant. The mean age at presentation was 55 (SD ± 15.8), with a slight female predilection (1.1:1). Patients experienced symptoms for a mean duration of 19.3 months, including neurological (93.9 percent) and endocrine (58.5 percent) disturbances. Among patients receiving treatment, 88.6 percent underwent surgery, 52.4 percent with a transsphenoidal/endonasal approach and 47.6 percent with a craniotomy. Additionally, 45.5 percent of patients received adjuvant external beam radiation. The median overall survival (OS) rate was 90.0 months for intrasellar chordoma, compared to 154.0 months for non-intrasellar skull base chordoma (Mantel-Cox, p=0.036). Patients aged 0-49 had a higher median OS than patients 50 or older (182.0 v. 63.0 months, p = 0.013). Adjuvant radiation did not result in a higher median OS (p = 0.48).

    Conclusions: Unlike intracranial chordoma, overall survival in intrasellar chordoma is not improved with adjuvant radiation. Young age predicts a better prognosis. Intrasellar chordoma has a lower overall survival than non-intrasellar skull base chordoma.

    Patient Care: This research will inform neurosurgeons and neurosurgery trainees on the presentation and management of intrasellar chordoma.

    Learning Objectives: By the conclusion of this session, participants should be able to: 1) Describe the presentation of intrasellar chordoma. 2) Identify the prognostic indicators of overall survival of intrasellar chordoma.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy